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Severe persistent stress incontinence following radical prostatectomy for prostate cancer treatment, although not very common,
remains the most annoying complication aﬀecting patient’s quality of life, despite good surgical oncological results. When severe
incontinence persists after the ﬁrst postoperative year and conservative treatment has been failed, surgical treatment has to be
considered. In these cases it is generally accepted that artiﬁcial urinary sphincter is the gold standard treatment. AUS 800 by
American Medical Systems has been successfully used for more than 35 years. Recently three more sphincter devices, the Flow-
Secure, the Periurethral Constrictor, and the ZSI 375, have been developed and presented in the market. A novel type of artiﬁcial
urinary sphincter, the Tape Mechanical Occlusive Device, has been inserted in live canines as well as in human cadavers. These new
sphincter devices are discussed in this paper focusing on safety and clinical results.
1.Introduction
In recent years, despite improvement in the surgical tech-
nique, the prevalence of Postprostatectomy Urinary Incon-
tinence (PPUI) has increased due to rising number of radical
prostatectomies performed annually [1]. Iatrogenic-induced
sphincter incompetence is the reason of postoperative stress
incontinence in 95% of cases. The reported PPUI rates vary
from 5% to 48%. This large variation may be attributed
mainly on the inﬂuence of the interviewing physician and
a lack of a standardized deﬁnition of “post prostatectomy
incontinence” [2].
Noninvasive therapy and particular pelvic ﬂoor muscle
training is the ﬁrst-line treatment for early incontinence
following prostatectomy within the ﬁrst 6 to 12 months [2].
Lifestyle interventions and pharmacotherapy (duloxetine)
are also recruited in this attempt [3, 4]. Despite this
conservative intervention, up to 10% of patients with PPUI
exhibit a persistent and moderate-to-severe incontinence for
more than one year postoperatively [5]. For these patients
surgical treatment is recommended [2].
The Artiﬁcial Urinary Sphincter (AUS) 800 (American
Medical Systems, Minnetonka, MN, USA), despite the new
surgical treatment options (slings, injection of bulking
agents, stem-cell therapy), remains the gold standard for
persistent moderate-to-severe stress urinary incontinence
due to Intrinsic Sphincter Deﬁciency (ISD) [1, 2, 6]. In
eﬀort to keep the good success rates and improve some
disadvantages of AUS 800 (high cost, complications, and
relative diﬃcult insertion), four new devices have been
developedinrecentyears[1].Weattempttopresenttechnical
characteristicsandinsertionproceduresforthesedevicesand
to report safety and eﬃcacy data, where they are available.
2.FlowSecureTM (RBM-Med)
The FlowSecure artiﬁcial urinary sphincter is a new prosthe-
sis for the management of urinary incontinence due to ISD
that has been designed and developed by Professors Craggs
M. D. and Mundy A. R. at London’s Institute of Urology and
Nephrology, in 2006 [7]. Unlike AUS 800, this sphincter is2 Advances in Urology
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Figure 1: FlowSecure artiﬁcial urinary sphincter.
an adjustable prosthesis ﬁlled with normal saline without
contrast. Plain X-rays cannot therefore be used for mon-
itoring, and ultrasound scan is the adequate radiographic
technique for evaluation. Except verifying prosthesis status,
ultrasound also allows measuring of the postvoid residual
volume and calculation of the urethral closing pressure [8].
Moreover, MRI can ensure the precise position and integrity
of all components of the sphincter [9].
TheFlowSecuresphincterisaone-piecedeviceconsisting
of two reservoirs placed in the paravesical space, a cuﬀ that
surrounds the urethra and a control pump with a self-
sealant port that is placed in patient’s scrotum (Figure 1).
The ﬁrst reservoir regulates resting urethral pressure and
the other relieves stress pressure during intra-abdominal
increase. During bladder ﬁlling the cuﬀ connected with
the pressure regulating reservoir compresses and keeps the
bulbarurethraclosedatlowpressure.Whenintra-abdominal
pressure rises, the stress relief balloon provides additional
pressure to the cuﬀ to maintain continence. The ﬂuid
pressure of the prosthesis may be regulated by injecting or
removing saline through the self-sealing port in the control
pump located in patient’s scrotum [10]. When the patient
wishes to void he only has to press the control pump until a
goodurineﬂowisachieved.Inthiswaythecuﬀisemptiedby
moving the ﬂuid from it to the pressure-regulating reservoir.
Redirection of ﬂuid ﬂow and ﬁlling of the cuﬀ is recovered
when compression on the pump stops [11].
Indications for implantation of the FlowSecure device in
order of signiﬁcance are postprostatectomy urinary incon-
tinence, incontinence due to congenital abnormalities, neu-
rogenic bladder with ISD, and women stress incontinence,
where other surgical procedures have failed [9–12].
Both perineal and suprapubic access are needed for
prosthesis implantation. Pressure-regulating and stress relief
reservoirsarelodgedinRetziusspacethroughthesuprapubic
incision. The cuﬀ is placed through the perineal incision
around the bulbar urethra as it is designed to transmit direct
pressure over the urethra. By blunt dissection a space is
created between the two incisions to pass the tubing, as well
as a subcutaneous space in the scrotum where control pump
is placed. FlowSecure is accompanied by a plastic trocar
and its obturator, which allows transposition of urethral
cuﬀ between Retzius space and perineum, and a tube of
glue for temporary ﬁxation of the belt over the cuﬀ when
adjusting it [11]. The control pump should be used as
soon as the scrotal edema disappears. In case of persistent
urinary retention, patients must be taught to perform
intermittent self-catheterizations until the problem resolves.
It is important that, during the catheterizations period, the
patient must use the control pump to empty the cuﬀ,e v e n
if he cannot void. The patient should be reevaluated for
continencestatus2to4weeksafterdischarge.Ifhemaintains
continence, the prosthesis does not need pressurization. In
those patients, who do not regain continence, pressurization
of the system must be carried out. Under strict aseptic
conditions, local anesthesia is administered at the scrotal
area where the control pump is located. Some saline is
injected through the self-sealing port using an orange 25G
15mm needle and a 10mL syringe. The needle must be
inserted longitudinal to the pump, to avoid damaging the
device. The prosthesis pressure is directly dependant on
the injected volume, following a pressure/volume curve.
Ideally, the ﬁrst pressurization reaches between 40 and 50cm
H2O, which normally takes about 4 to 6mL of saline. The
patient is advised to be re-evaluated two weeks after initial
pressurization. At this time, ﬂuid can be added or removed
from the system to accommodate to the patient’s needs. It is
notadvisable,duringsubsequentpressurization,toaddmore
than 2mL of saline per session [9]. Proper device function
must be monitored by free uroﬂowmetry, ultrasound scan,
and clinical history [8].
Knight et al. presented 9 male patients (mean age
66 years) with urodynamically proven stress incontinence
due to radical prostatectomy treated with implantation of
FlowSecure sphincter. The patients were followed for a
minimum period of 12 months. All 9 patients recovered well
from surgery. Two devices had to be removed for technical
reasons. The mean leakage for the remaining 7 patients
prior to implantation was 771 ± 658mL corresponding to
a continence index of 54%. Twelve months later the leakage
had statistically signiﬁcantly reduced to 52 ± 36mL (P<
0.05) and the continence index increased to 97%. There
was no signiﬁcant diﬀerence in bladder capacity or ﬂow
rate. Four patients required additional pressurization to
achieve optimal continence and this was carried out without
complication [13]. In another study by Rodriguez et al.
100 patients with stress urinary incontinence of various
etiologies underwent bulbar urethra (96%) or bladder neck
(4%) implantation of a FlowSecure device. All patients
had tried conservative treatments and also 59 patients had
undergone unsuccessful surgical procedures (suburethral
slings, bulking agents, Proact, and AUS-800). Nine patients
had undergone previous pelvic radiotherapy. At implanta-
tion the sphincters’ pressure was left at atmospheric level
in all cases. Patients attended for initial pressurization 2–
4 weeks postoperatively and were recalled at two-week
periods for evaluation and repeat pressurization, if it was
required. Overall,3pressurizations procedureswererequired
to achieve socially satisfactory continence in 89 patients. The
implantingprocedurelastedinaverage38–47minutes.Mean
inpatientstaywas4.3days.53patientshadpostoperativeself-
limited scrotal hematoma. Implants had to be removed inAdvances in Urology 3
28 patients (28%) due to early infection (8%), late infection
secondary to pressurization procedures (5%), perforation of
the pump at pressurization (9%), and mechanical failure
(6%). No erosions were noted [14].
The main advantage of FlowSecure device over AUS 800
is that while the later exerts a high constant pressure over
the urethra, the former increases pressure on the urethra
instantly, only during stress increase of intra-abdominal
pressure. During the deactivated position the cuﬀ turns back
to the initial low pressure not exceeding 40cm H2O, thus
minimizing danger for urethral erosion [11].
In conclusion, FlowSecure artiﬁcial urinary sphincter is
easy to implant, with low risk of mechanical failure, and
adjustabletothepatient’scontinenceneeds.Itsmainpurpose
is to achieve total patient continence during periods of
raised abdominal pressure while subjecting urethra to the
lowest possible pressure during resting. Urethral ischemia
potentially leading to atrophy and erosion is thus prevented
[8]. Use of one-piece prosthesis also decreases the risk of
infection due to intraoperative handling and minimizes the
chance of mechanical failure derived from errors during
assembly [13]. All these may predict a promising future.
However, more time and studies will be needed to deﬁne
the role of this sphincter in the management of stress
incontinence resistant to other treatments.
3.PeriurethralConstrictor (Silimed,
Rio de Janeiro, Brazil)
The Periurethral Constrictor (PUC) was developed by Dr.
Fabio Vilar in 1996. It was designed for implantation
in pediatric patients to treat deﬁcient bladder sphincter
function [15]. The PUC is a one-piece, two-part device. It
is comprised of a constrictor cuﬀ linked by a 20cm silicone
tube to a valve, which is elliptical in shape and rounded at
the edges (Figure 2)[ 16]. The adjustable cuﬀ is implanted
around the bladder neck through suprapubic approach or
bulbous urethra through perineal incision [17]. The valve
is placed in a space accessible by percutaneous puncture,
usuallyinthesubcutaneousspacebetweentheumbilicusand
theiliaccrest.Theinjectionportisdesignedtoaccommodate
a ﬁne Huber needle [18].
The system works hydraulically by the injection of sterile
saline solution through the self-sealing valve in order to
promoteastaticocclusivepressureonthecuﬀ.Theactivation
of the PUC takes place 6–8 weeks after implantation surgery.
This requires ﬁlling the bladder and then injecting further
saline into the system for as long as the occlusive pressure
obtained allows good urine ﬂow without signiﬁcant increase
of the post void residual urine volume [16].
A limited number of studies with controversial results
have been published for using PUC in PPUI, excluding
studies focused in its use in pediatric population, especially
for the treatment of neurogenic urinary incontinence due
to ISD [15, 18, 19]. In a study performed by Simone et
al. 43 patients with mild urinary incontinence following
radical prostatectomy were treated by PUC implantation.
Overallsuccessfulratewas86%. Postoperative complications
Value
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Figure 2: The Periurethral Constrictor.
occurred in 6 patients (1 hematoma, 1 erosion, 2 infections,
and 2 malfunctioning devices). Only the ﬁrst two compli-
cations were managed by device removal [20]. Schiavini
et al. retrospectively studied 30 patients with PPUI and
PUC implantation for a mean period of 42.1 months. At
the time of implantation the reported mean use of pads
was 4.4 per day. In 22 patients (73.3%) the devices were
functional leading to a good continence result. In 7 patients
the device was removed because of cuﬀ erosion (4 patients,
13.3%) and infection (3 patients, 10%). An eighth patient
remained incontinent after the device reactivation because
of detrusor hyper-reﬂexia [16]. On the other hand, Lima
et al. presented a study with 82.2-month mean followup
which reported a very high device removal rate 41.07% [17].
The average time between surgery and the removal of the
devicewas22.6months.Themostfrequentcomplicationwas
urethral erosion in 15 patients (26.78%). Comparing erosion
rates of AUS 800, ranging from 1.7% to 4.5%, the present
study presented higher rates [21]. Other complications were
mechanical malfunction in 5 (8.9%), urethral stenosis in 3
(5.3%),urinaryﬁstulain2(3.5%),infectionin2(3.5%),and
persistent urinary tractinfection in 1 case (1.7%). In patients
in whom the device was not removed (33), only 17 from
them were continent, representing an overall success rate of
30.35% [17].
The above results, suggest that further studies are
required to determine the safety and eﬃcacy of this type of
artiﬁcial urinary sphincter. However, simplicity and low cost
of PUC are important characteristics in its favor comparing
with AUS 800 [16]. The one-piece design makes the device
easier to implant and the absence of connections reduces
the chances for leakage and kinks [19]. The characteristics
of the cuﬀ allow spontaneous voiding and catheterization
without the need of previous emptying the cuﬀ.I tc a nb e
deactivated, under activated or reactivated at any time by
simplypunctuatingthesubcutaneousport toaddorsubtract4 Advances in Urology
Cuff Pump
Figure 3: The ZSI 375.
ﬂuid [18]. Based on these observations, more studies are
needed to bring safer conclusions.
4.ZSI375(ZEPHYRSurgicalImplants,
Swiss-French)
ZSI 375 is an artiﬁcial urinary sphincter produced by
ZEPHYR Surgical Implants, a Swiss-French company. The
system was designed and created by Dr. Christophe Gomez-
Llorens and Raphael Gomez-Llorens in 2005 [22]. It is used
to treat severe urinary incontinence due to ISD. The ZSI
375 is a one-piece medical device that can be implanted
only in men. It is made by silicone elastomer and ﬁlled with
sterile normal saline solution. It consists of an inﬂatable
and adjustable cuﬀ that ﬁts around the urethra and a pump
with an embedded pressure-regulating tank placed in the
scrotum connected with the cuﬀ by a 110mm silicone tube
(Figure 3). The maximal pressure in the cuﬀ must not exceed
350mbar. The ZSI 375 is ﬁlled by normal saline solution.
Therearetwocompartmentsinthedevice:ahydrauliccircuit
and a compensation pouch circuit separated by a piston.
Spontaneously, the spring pushes the piston up and the
piston pushes the saline solution of the hydraulic circuit into
the cuﬀ. The pressure in the hydraulic circuit is not the only
factor of the cuﬀ eﬃciency. To obtain a good continence
result, the deﬂated cuﬀ must compress the urethra. The ZSI
375hastheadvantagetoincreasetheissuedpressureandgive
the chance to readjust the cuﬀ [22].
Two incisions are needed for the implantation of the
device. Through a perineal incision the cuﬀ is placed around
the bulbar urethra. The pump unit is placed in a subdartos
pouch through an inguinal incision. Six to eight weeks later
the device is activated by pressing an activation button. If
necessary, it is possible to inject 1 or 2mL of normal saline
in the compensation pouch through the scrotum to increase
the issued pressure [22].
The advantages of ZSI 375 over AUS 800 are reduced
cost, the opportunity to adjust the issued pressure of the
device, and the possibility to re-adjust the cuﬀ in case of
postoperative urethral atrophy [22].
In a study performed by Sandul et al. 34 men with urine
incontinence after treatment for prostate cancer were treated
by ZSI 375. Thirty-two of them had radical prostatectomy,
six of those also had adjuvant radiotherapy, and two had
brachytherapy followed by TURP to relieve outlet obstruc-
tion. Eight patients had already undergone a male perineal
sling operation. Initial sphincter closure pressure was elected
to be 60–70cm H2O. 60% of the patients needed further
increase of the pressure, something which was performed
as an oﬃce procedure. The interval for primary activation
ranged from 4 to 6 weeks. With a maximum followup of 20
months, no surgical revision was necessary for mechanical
malfunction. Infection of the device occurred in 2 (5.8%)
patients requiring device removal. Overall, social acceptable
continence was achieved in 94.2% (32 patients) [23]. Llorens
et al. studied 17 men, after 1 year of implantation of the ZSI
375. 14 patients were incontinent after radical prostatectomy
and 3 patients after TURP. All patients had tried previous
conservative treatments without success. Total continence
was deﬁned as dry, and social continence was deﬁned as
a minimal leakage requiring at the most one pad daily
with activity. All other results were deﬁned as incontinence.
In14 patients the initial pressure adjusted to 60–70cm H2O
and in 3 patients to 70–80cm H2O. Mean hospitalization
duration was three days. Implantation and recovery were
uneventful for 12 patients. Four patients in whom the pump
unit was implanted through the perineal incision presented
permanent scrotum edema making the manipulation of the
pumpdiﬃcult.Thisledtothereimplantationofthepumpin
asubdartosscrotalpouchthroughascrotalincision.Afterre-
implantation, one patient presented extrusion of the pump
unit and the device had to be removed. Finally one patient
presented infection leading to artiﬁcial sphincter removal
ﬁve days after the procedure. None of the remaining 15
patients demonstrated bladder overactivity, chronic urinary
retention, or any other adverse eﬀect. According to the
results the three patients implanted with 70–80cm H2O
issued pressure in the system were dry. For the 12 patients
implanted with the 60–70cm H2O issued pressure in the
system, three became completely dry, three achieved social
continence, and six were still incontinent using two to three
pads per day. Eleven patients implanted with 60–70cm
H2O were initially satisﬁed with their continence results.
However, after in-situ injection of one mL of saline solution
in the compensation pouch, the issued pressure increased
10cm H2O to 70–80cm H2O and the patients improved
or achieved social continence [22]. 70–80cm H2Os e e m st o
be the most eﬃcient issued pressure because the pressure-
regulating system of ZSI 375 is not submitted to abdominal
pressure.
The innovative features of the ZSI 375 are the following:
it is a one-piece device thus facilitating preparation and
implantation; it contains an adjustable cuﬀ m o u n t e di na
curve to reduce creasing and fracture danger; it oﬀers the
possibility to increase the issued pressure of the device in situ
achieving better continence results; ﬁnally, preparation and
implantation of the ZSI 375 are technically simple and quickAdvances in Urology 5
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Figure 4: The Tape Mechanical Occlusive Device.
with no serious adverse events associated with the device
[22].
5 .T h eT apeM ec h anic alO c c l usi v eDevic e
(GTUrological,Minneapolis,MN)
A new type of artiﬁcial sphincter is being developed utilizing
a spring-loaded mechanism for applying circumferential
pressure in the urethra, which is easy to implant and
simple to use. This artiﬁcial urinary sphincter is the Tape
Mechanical Occlusive Device (TMOD) (GT Urological LLC,
Minneapolis, MN), a one-piece device that is manually
controlled by the patient through its ON/OFF buttons [24].
The TMOD is a totally implantable, one-piece artiﬁcial
urinary sphincter (Figure 4) consisting of an occlusive tape
and a conduit tape, connected to a control mechanism.
The conduit tape originates at the control mechanism
and the occlusive tape connects to the conduit tape. The
conduit tape is of suﬃcient length to allow placement of the
occlusive tape at the bulbous or penoscrotal urethra without
creating undue tension on the conduit tape. The scrotally
implanted control mechanism consists of a titanium casing,
housing a three-metal alloy spring that applies tension to
sutures running through the conduit and occlusive tapes.
The control mechanism has ON and OFF buttons and is
covered with a ﬂexible silicone boot that prevents tissue in-
growth. The boot has a port for injection of saline into the
device that displaces air and creates an isotonic interior. This
same port is designed for antibiotic ﬂushing per surgeon
discretion. In the ON position, the occlusive tape contracts
and is designed to apply radial pressure to the urethra of
50–80cm of water. The degree of radial pressure was chosen
from clinical experience with the AUS 800 in order to limit
urine leakage while minimizing urethral perfusion. There is
a locking clip that locks the occlusive tape to itself to form
an annular occlusive ring around the urethra. This can easily
be unclipped for tape removal if repositioning or removal of
the TMOD is required. Suture tabs are attached to both the
control mechanism and occlusive tape to anchor the device
in place and prevent migration [24].
In humans is anticipated to implant the occlusive tape in
an open, deactivated condition, allowing it to remain in that
condition for 6 weeks postoperatively to permit healing. The
physician would then activate the device to apply pressure
to the urethra by depressing the ON button through the
intact scrotal skin. The patient can then depress the control
mechanism OFF button to again remove occlusive pressure
from the urethra and allow for unobstructed voiding or
lock it in the deactivated position for voiding or nocturnal
deactivation. To reactivate, the patient can push the ON
button [24].
The TMOD has been implanted in canines to assess its
functionality, occlusive eﬃciency, and biocompatibility and
in human male cadavers to assess its occlusive eﬃciency and
sizing, with encouraging results. Activation of the implanted
TMOD resulted in intraurethral pressures within the desired
range of 50–80cm H2O .T h ed e v i c eh a sp r o v e nt oh a v en o
evidence of systemic toxicity. It has met the requirements for
reliability and biocompatibility [24].
The TMOD seems to oﬀer several advantages over the
currently available AUS 800. It is a single piece device
that does not require assembly reducing preparation time
by operating room staﬀ. It is nonhydraulic and requires
no pressure-regulating balloon placement leading to less
dissection. The reduced width of the tape minimizes the
dissection around the bulbar urethra reﬂecting a lower risk
of urethral injury during the operation. The simplicity of
the ON/OFF button operation allows easier patient control.
The TMOD has not been implanted in live human patients
yet and human clinical trials should follow given the proof
of technical feasibility, biocompatibility, and lack of systemic
toxicity.
6. Conclusion
The ﬁrst artiﬁcial urinary sphincter was introduced in 1973
to treat ISD [25]. After its introduction the basic device
design changed to the ﬁfth-generation model, the AUS 800,
in 1983 [26]. Despite its good success rate, in order to
decrease mechanical failure, numerous changes have been
made to the various components of this device; however,
its basic design and mode of operation have remained
unchanged for over 20 years. Recently, new devices have
been developed to overcome the disadvantages of AUS 800.
The controversial results in success and complication rates
emphasize that these new devices need to be implanted
in greater numbers of patients and with longer follow-up
periods. If this experience reveals that one or more of them
present potential advantages, these new artiﬁcial urinary
sphincterswillbecomeanimportanttoolinthemanagement
of men suﬀering from PPUI owing to ISD.
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